A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM)
Abstract:Background
Renal impairment (RI) caused by deposition of Multiple myeloma (MM) derived free light chains (FLC), is associated with worse MM patient outcomes. Reciprocally, early reduction of serum-FLC improves survival. Proteasome inhibitors (PIs), which target immunoglobulin production in MM, have improved MM survival times but PI-resistance is a major problem. Therefore, novel treatments that target MM cell survival and block FLC secretion are urgently required.
Methods
MM cell lines and primary cells were… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.